Themis signs manufacturing/supply deal with Novartis for TPM/diclofenac gel

On 12th April, Phosphagenics' commercial partner, Themis Medicare, entered into a licence and supply agreement with Novartis India, in which Themis will manufacture and supply diclofenac topical gel formulated using Phosphagenics' Targeted Penetration Matrix (TPM) transdermal drug-delivery system, to Novartis. The drug-delivery system is available only with Themis in India.

Themis signs manufacturing/supply deal with Novartis for TPM/diclofenac gel

On 12th April, Phosphagenics' commercial partner, Themis Medicare, entered into a licence and supply agreement with Novartis India, in which Themis will manufacture and supply diclofenac topical gel formulated using Phosphagenics' Targeted Penetration Matrix (TPM) transdermal drug-delivery system, to Novartis. The drug-delivery system is available only with Themis in India.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.